BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang J, Wu Y, Bi Q, Zheng X, Zhang J, Huang W. Adverse outcomes of proton pump inhibitors in chronic liver disease: a systematic review and meta-analysis. Hepatol Int 2020;14:385-98. [PMID: 31912308 DOI: 10.1007/s12072-019-10010-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Wu S, Yu Y. Aspirin Use and the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Front Med (Lausanne) 2020;7:569759. [PMID: 33490093 DOI: 10.3389/fmed.2020.569759] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Terres AZ, Balbinot RS, Muscope ALF, Longen ML, Schena B, Cini BT, Luis Rost G Jr, Balensiefer JIL, Eberhardt LZ, Balbinot RA, Balbinot SS, Soldera J. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterol Hepatol 2021:S0210-5705(21)00086-8. [PMID: 33746028 DOI: 10.1016/j.gastrohep.2021.02.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Piano S, Angeli P. Bacterial Infections in Cirrhosis as a Cause or Consequence of Decompensation? Clin Liver Dis 2021;25:357-72. [PMID: 33838855 DOI: 10.1016/j.cld.2021.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Veettil SK, Sadoyu S, Bald EM, Chandran VP, Khuu SAT, Pitak P, Lee YY, Nair AB, Antony PT, Ford AC, Chaiyakunapruk N. Association of proton-pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol 2021. [PMID: 34622475 DOI: 10.1111/bcp.15103] [Reference Citation Analysis]
5 Wu S, Jiang P, Zhao XM, Chen WH. Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis. Cell Metab 2021;33:455-6. [PMID: 33657385 DOI: 10.1016/j.cmet.2021.02.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Oh TG, Kim SM, Atkins AR, Yu RT, Downes M, Evans RM, Loomba R. Proton pump inhibitor use status does not modify the microbiome signature for cirrhosis. Cell Metab 2021;33:457. [PMID: 33657386 DOI: 10.1016/j.cmet.2021.02.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Cheung KS, Mak LY, Lam LK, Fung J, Liu F, Seto WK, Yuen MF. Statins associate with better clinical outcomes in chronic hepatitis B patients with HBsAg seroclearance. Hepatol Int 2021;15:881-91. [PMID: 33988834 DOI: 10.1007/s12072-021-10197-4] [Reference Citation Analysis]
8 Voicu MN, Popescu F, Florescu DN, Rogoveanu I, Turcu-Stiolica A, Gheonea DI, Iovanescu VF, Iordache S, Cazacu SM, Ungureanu BS. Clostridioides difficile Infection among Cirrhotic Patients with Variceal Bleeding. Antibiotics (Basel) 2021;10:731. [PMID: 34204307 DOI: 10.3390/antibiotics10060731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Jacques ROC, Massignan LDS, Winkler MS, Balbinot RS, Balbinot SS, Soldera J. ACUTE-ON-CHRONIC LIVER FAILURE IS INDEPENDENTLY ASSOCIATED WITH LOWER SURVIVAL IN PATIENTS WITH SPONTANEOUS BACTERIAL PERITONITIS. Arq Gastroenterol 2021;58:344-52. [PMID: 34705969 DOI: 10.1590/S0004-2803.202100000-58] [Reference Citation Analysis]